In response to the discontinuation of Movapo, an essential medication for managing hypomobility in advanced Parkinson’s disease, Canadians now have access to an alternative treatment option. APO-go® PEN, containing the ingredient apomorphine hydrochloride, has been granted exceptional, temporary importation status by Health Canada.

APO-go® PEN, already available in the United Kingdom with the same active ingredients as Movapo, fills the gap left by the discontinued medication. This temporary importation provides relief for individuals who relied on Movapo or may benefit from this treatment in Canada.

Although APO-go® PEN is now available by prescription at pharmacies nationwide, it is currently not eligible for reimbursement through public or private drug plans. This means individuals prescribed with APO-go® PEN will bear the full cost of the medication.

Recognizing the financial burden this may impose on Parkinson’s patients, there is work underway with Health Canada to explore reimbursement solutions for APO-go® PEN. 

For individuals previously using Movapo, it is advised to consult with healthcare providers and pharmacists to assess the suitability of transitioning to APO-go® PEN. Healthcare providers can access comprehensive information on APO-go® PEN usage from the Canadian Product Monograph for Movapo available on the Health Canada Drug Product Database.

Reporting of adverse drug reactions associated with APO-go® PEN should be directed to Aguettant Canada Inc. by email at safety@aguettant.ca or by phone toll-free at 1-833-772-6294. Additionally, adverse reactions should be reported to Health Canada through their website or at 1-866-234-2345.

For inquiries regarding APO-go® PEN, individuals are encouraged to reach out to Aguettant Canada Inc. directly at the contact information provided above.

In summary:

• Movapo has been discontinued in Canada.
• APO-go® PEN, granted exceptional importation status, is now available for Canadians.
• APO-go® PEN can be obtained by prescription but is not currently reimbursable through drug plans.
• Individuals considering switching from Movapo to APO-go® PEN should consult healthcare providers.
• Adverse reactions related to APO-go® PEN should be reported to Aguettant Canada Inc. and Health Canada.

(This information was provided based on supporting documentation produced by Parkinson Canada)